 Altimmune Inc. ALT shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didnt work as well as anticipated. Altimmune shares fell 33 after hours, following a 2.5 decline to close at 15.90. 